These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19249973)

  • 1. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J; Egan W; Vicari G; Furesz J; Schild G
    Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency testing of veterinary vaccines: the way from in vivo to in vitro.
    Romberg J; Lang S; Balks E; Kamphuis E; Duchow K; Loos D; Rau H; Motitschke A; Jungbäck C
    Biologicals; 2012 Jan; 40(1):100-6. PubMed ID: 22075457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensuring the quality, potency and safety of vaccines during preclinical development.
    Lebron JA; Wolf JJ; Kaplanski CV; Ledwith BJ
    Expert Rev Vaccines; 2005 Dec; 4(6):855-66. PubMed ID: 16372881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistency testing of diphtheria and tetanus to replace potency testing for lot release.
    Kreeftenberg JG
    Dev Biol (Basel); 2002; 111():291-8. PubMed ID: 12678252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory processes and three Rs alternatives.
    Milstien J
    Dev Biol (Basel); 2002; 111():15-9. PubMed ID: 12678220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three Rs potential in the development and quality control of pharmaceuticals.
    Hartung T
    ALTEX; 2001; 18 Suppl 1():3-13. PubMed ID: 11854852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A short history of the use of animals in vaccine development and quality control.
    Hendriksen CF
    Dev Biol Stand; 1996; 86():3-10. PubMed ID: 8785959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical evaluation of numbers of animals to be used in vaccine potency testing: a practical approach.
    Akkermans AM; Hendriksen CF
    Dev Biol Stand; 1999; 101():255-60. PubMed ID: 10566799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
    Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
    Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of an in vitro potency test for the Cuban hepatitis B vaccine.
    Landys Chovel Cuervo M; Reyes Huerta N
    Dev Biol (Basel); 2002; 111():305-12. PubMed ID: 12678254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological methods for potency testing of tetanus toxoid vaccines for human use.
    Hendriksen C; Winsnes R
    Dev Biol (Basel); 2002; 111():131-40. PubMed ID: 12678232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ["Replacement Methods to Animal Testing" as the incentive topic of the German Ministry of Education and Research. Selected results on biological drugs].
    Diekmann W; Hansper M
    ALTEX; 2001; 18(1):23-8. PubMed ID: 11248846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in reduction and replacement of in vivo toxicity and potency tests for pertussis vaccines.
    Xing D; Canthaboo C; Douglas-Bardsley A; Yuen CT; Prior S; Liu Y; Corbel M
    Dev Biol (Basel); 2002; 111():57-68. PubMed ID: 12678225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developments in pertussis vaccines leading to reduction and replacement of in vivo testing.
    Redhead K
    Dev Biol Stand; 1996; 86():263-70. PubMed ID: 8785955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoption of three Rs alternatives for regulatory testing of vaccines in the developing world: possibilities and barriers.
    Di Fabio JL; Jaramillo MT; Arciniega JL
    Dev Biol (Basel); 2002; 111():195-8. PubMed ID: 12678241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The consistency approach for the quality control of vaccines.
    Hendriksen C; Arciniega JL; Bruckner L; Chevalier M; Coppens E; Descamps J; Duchêne M; Dusek DM; Halder M; Kreeftenberg H; Maes A; Redhead K; Ravetkar SD; Spieser JM; Swam H
    Biologicals; 2008 Jan; 36(1):73-7. PubMed ID: 17892948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of marker vaccine and differential diagnostic test technology.
    Henderson LM
    Biologicals; 2005 Dec; 33(4):203-9. PubMed ID: 16257545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.